Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.33 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691603 | 0.79 | PRKCI (0.44) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL29700716 | 0.79 | PRKCI (0.44) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL1689372 | 0.76 | DYRK1A (0.46) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL12463243 | 0.76 | ADORA2A (0.42) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL23147654 | 0.76 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL13666508 | 0.76 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL3124523 | 0.76 | PRKCI (0.46) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL17731733 | 0.76 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL760829 | 0.76 | CHUK (0.51) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL31507871 | 0.76 | CHUK (0.51) | PRKCIAXLADORA2AADORA1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | UNIVERSITY OF WINDSOR (CA) | 2025-03-13 | — | — | US | disclosed |
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-115916747-A | Fused heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022002118-A1 | FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-102171211-A | Piperidine derivatives useful as JAK3 inhibitors | BIOCRYST PHARM INC | 2011-08-31 | — | — | CN | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | PRKCI 419/4885AXL 2045/4885ADORA2A 2515/4885 |
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | CDK4, CDK3, CDKN1A | PRKCI 631/4885AXL 1293/4885ADORA2A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.